Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Morabito

Showing results (131-140 of 198) with videos related to

Pageof 20
Sort By:
Cancers|September 28, 2019
Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with GefitinibRiziero Esposito Abate, Raffaella Pasquale, Alessandra Sacco, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2016
Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancerFederico Cappuzzo, Alessandro Morabito, Nicola Normanno, et al.
The Oncologist|April 19, 2019
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World PopulationLucio Crinò, Paolo Bidoli, Angelo Delmonte, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trialAlessandro Morabito, Gennaro Daniele, Raffaele Costanzo, et al.
BMC Cancer|May 14, 2021
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trialsPiera Gargiulo, Laura Arenare, Cesare Gridelli, et al.
Critical Reviews in Oncology/Hematology|January 31, 2009
Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective studySandro Pignata, Gabriella Ferrandina, Giovanna Scarfone, et al.
Lung Cancer (Amsterdam, Netherlands)|April 22, 2009
Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trialsCesare Gridelli, Alessandro Morabito, Vittorio Gebbia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2009
Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trialEmanuela Rossi, Alessandro Morabito, Francesca Di Rella, et al.
Future Oncology (London, England)|November 15, 2017
Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancerGiulio Metro, Antonio Passaro, Giuseppe Lo Russo, et al.
Exploration of Targeted Anti-Tumor Therapy|September 1, 2022
Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancerGiuliano Palumbo, Giovanna Esposito, Guido Carillio, et al.
Pageof 20

Showing results (131-140 of 198) with videos related to

Sort By:
Pageof 20
Cancers|September 28, 2019
Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with GefitinibRiziero Esposito Abate, Raffaella Pasquale, Alessandra Sacco, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2016
Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancerFederico Cappuzzo, Alessandro Morabito, Nicola Normanno, et al.
The Oncologist|April 19, 2019
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World PopulationLucio Crinò, Paolo Bidoli, Angelo Delmonte, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trialAlessandro Morabito, Gennaro Daniele, Raffaele Costanzo, et al.
BMC Cancer|May 14, 2021
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trialsPiera Gargiulo, Laura Arenare, Cesare Gridelli, et al.
Critical Reviews in Oncology/Hematology|January 31, 2009
Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective studySandro Pignata, Gabriella Ferrandina, Giovanna Scarfone, et al.
Lung Cancer (Amsterdam, Netherlands)|April 22, 2009
Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trialsCesare Gridelli, Alessandro Morabito, Vittorio Gebbia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2009
Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trialEmanuela Rossi, Alessandro Morabito, Francesca Di Rella, et al.
Future Oncology (London, England)|November 15, 2017
Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancerGiulio Metro, Antonio Passaro, Giuseppe Lo Russo, et al.
Exploration of Targeted Anti-Tumor Therapy|September 1, 2022
Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancerGiuliano Palumbo, Giovanna Esposito, Guido Carillio, et al.
Pageof 20